Skip to content

Biotech Sector

3 Top Biotech Stocks To Watch This Week

Biotech stocks are often seen as a segment of the market that has the potential to thrive regardless of the broader stock market sentiment. Essentially, biotech companies are high-risk, high-reward investments. This is because each stage of progress can be a catalyst for the stocks. A positive outcome can change the fortune of the company. But, a negative one could… 

The Biotech Industry’s Promising Growth Prospects – And 2 Picks For Outsized Returns

“In a world where interest rates are so low and uncertainty seems to be the norm, baby boomers need to look for stable dividend stocks that can compete with the current income of longer-term Treasury notes “Favorable government regulations, coupled with the introduction of new and sophisticated products, and growing demand for synthetic biology, should keep driving the biotech industry’s… 

Lead Products With Great Potential Make These 2 Top Biotech Stocks To Consider

The author of today’s article advises that “before investing in a biotech company, it’s essential to look at the financial opportunity offered by its current lineup of products (or most promising pipeline candidates), both in the short and long run.” With that, they proceed to highlight two biotech stocks that could be top picks right now based on the great… 

Wall Street Analysts See 150%+ Gains For These 2 Biotech Stocks In The Coming Months

While the biotech industry’s near-term potential is largely tied to the development of treatments for COVID-19, the author of today’s article notes that “The sector’s long-term potential remains solid due to the aging population and the rising cost of healthcare.” Against this backdrop, they proceed to highlight two biotech stocks that Wall Street analysts expect will see significant gains of… 

Get A Leg Up From “The Novel Drug Craze”

Although a controversial decision, the FDA has approved Biogen’s Alzheimer’s drug, Aduhelm – and the decision caused Biogen’s stock to surge more than 60% in one day. On the heels of this, and with novel drug approvals on the rise, the contributors to today’s article discuss Biogen’s approval “and how ‘novel’ drugs can give biotech stocks a leg up …… 

When It Comes To Biotech Stocks, Size Matters

“A big, headline-grabbing company is not always your best bet, assuming you’re a shrewd investor seeking to maximize your profits,” advises the author of today’s article – and this may be especially true when it comes to biotech stocks. What two “size benefits” do smaller companies have – and why does the “size factor” work? CLICK HERE.

As The Regulatory Environment For Biotech Changes, These 6 Pharma Stocks Have Been Downgraded

With new leadership at the federal agencies that oversee the drug industry, a top Wall Street analyst is warning that the biotech industry and biotech investors “will need to adjust to a different regulatory environment to the one they have enjoyed for the last 5 years” – and has downgraded six pharma stocks due, in part, to the prospect of… 

A Short Biotech Idea

The small-cap biotech company featured in today’s article experienced a remarkable rally over the last few months. However, with the FDA having just approved its most advanced asset, a treatment for ADHD, the author believes that this “exhausts the company’s largest catalyst, and [they] do not see any material new catalysts any time soon.” With that, and with doubts about… 

Better Know These Lesser-Known Biotech Stocks That Have Been Surging

As the biotech sector has received increased investor focus over the past year amid the COVID-19 pandemic, the author of today’s article notes that “Even the smaller and lesser known are being seen now as having immense potential; Many of these companies are working tirelessly toward new drug developments and eyeing larger collaborations.” With that, she proceeds to highlight three… 

While Some Biotech/Drug Stocks Were Hit Hard By COVID This Year, These 6 Thrived Because Of It

While the pharma/biotech sector was not spared COVID-19 pain this year, with various companies hit hard by disruptions in clinical studies and delays in elective surgeries and in individuals seeking medical care, the authors of today’s article note that “some biotech stocks have more than doubled during this period, especially those focusing on developing a coronavirus vaccine.” They proceed to…